Cargando…

Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives

SIMPLE SUMMARY: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contributio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellerin, Laurence, Carrié, Lorry, Dufau, Carine, Nieto, Laurence, Ségui, Bruno, Levade, Thierry, Riond, Joëlle, Andrieu-Abadie, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692067/ https://www.ncbi.nlm.nih.gov/pubmed/33121001 http://dx.doi.org/10.3390/cancers12113147

Ejemplares similares

New Insights into the Role of Sphingolipid Metabolism in Melanoma
por: Carrié, Lorry, et al.
Publicado: (2020)

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
por: Bilal, Fatima, et al.
Publicado: (2019)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes
por: Milhas, Delphine, et al.
Publicado: (2012)

The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer
por: Dubot, Patricia, et al.
Publicado: (2022)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Caspase-10-Dependent Cell Death in Fas/CD95 Signalling Is Not Abrogated by Caspase Inhibitor zVAD-fmk
por: Lafont, Elodie, et al.
Publicado: (2010)

Sphingolipids modulate the epithelial–mesenchymal transition in cancer
por: Levade, T, et al.
Publicado: (2015)

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma
por: Mrad, Marguerite, et al.
Publicado: (2016)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses
por: Dubot, Patricia, et al.
Publicado: (2020)

Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells
por: Chartrain, Marine, et al.
Publicado: (2012)

IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis
por: Mas, Emmanuel, et al.
Publicado: (2009)

Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells
por: Carrier, Arnaud, et al.
Publicado: (2022)

Targeting Lipid Metabolic Reprogramming as Anticancer Therapeutics
por: Cha, Ji-Young, et al.
Publicado: (2016)

Novel therapeutic mechanisms determine the effectiveness of lipid-core nanocapsules on melanoma models
por: Drewes, Carine C, et al.
Publicado: (2016)

TNF-R1, an immune checkpoint in melanoma?
por: Bertrand, Florie, et al.
Publicado: (2015)

Perspectives of lipid metabolism reprogramming in head and neck squamous cell carcinoma: An overview
por: Miao, Xiangwan, et al.
Publicado: (2022)

Plasticity of melanoma and EMT-TF reprogramming
por: Tulchinsky, Eugene, et al.
Publicado: (2013)

DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness
por: Carrier, Arnaud, et al.
Publicado: (2022)

Genetic reprogramming of host cells by bacterial pathogens
por: Tran Van Nhieu, Guy, et al.
Publicado: (2009)

Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
por: Jin, Hao-Ran, et al.
Publicado: (2023)

Lipid metabolic reprogramming in cancer cells
por: Beloribi-Djefaflia, S, et al.
Publicado: (2016)

Lipid Metabolic Reprogramming in Hepatocellular Carcinoma
por: Nakagawa, Hayato, et al.
Publicado: (2018)

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
por: Falletta, Paola, et al.
Publicado: (2017)

Reprogrammed Lipid Metabolism and the Lipid-Associated Hallmarks of Colorectal Cancer
por: Salita, Timothy, et al.
Publicado: (2022)

Demethylation by low-dose 5-aza-2′-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma
por: Desjobert, Cécile, et al.
Publicado: (2019)

Epigenetic reprogramming of melanoma cells by vitamin C treatment
por: Gustafson, Christopher B, et al.
Publicado: (2015)

Geometric regulation of histone state directs melanoma reprogramming
por: Lee, Junmin, et al.
Publicado: (2020)

Cellular Reprogramming—A Model for Melanoma Cellular Plasticity
por: Granados, Karol, et al.
Publicado: (2020)

MITF reprograms the extracellular matrix and focal adhesion in melanoma
por: Dilshat, Ramile, et al.
Publicado: (2021)

The role of lipid metabolic reprogramming in tumor microenvironment
por: Yang, Kai, et al.
Publicado: (2023)

Lipid metabolism reprogramming in head and neck cancer
por: Liang, Jinfeng, et al.
Publicado: (2023)

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer: The function of lipid metabolism reprogramming in pancreatic cancer
por: Guo, Duancheng, et al.
Publicado: (2023)

Reprogramming Neutral Lipid Metabolism in Mouse Dendritic Leucocytes Hosting Live Leishmania amazonensis Amastigotes
por: Lecoeur, Hervé, et al.
Publicado: (2013)

Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets
por: Prouteau, Anais, et al.
Publicado: (2022)

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies
por: Colin, Laurence, et al.
Publicado: (2009)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1notkse0er8a9cqe53i0jsl16n